Risk of Cardiovascular Events in Patients with Hypertriglyceridemia: A Review of Real-World Evidence.
Statin-treated patients have substantial residual cardiovascular disease risk despite control of low-density lipoprotein cholesterol. Other modifiable atherogenic lipids and lipoproteins, such as triglycerides and triglyceride-rich lipoproteins, are likely responsible for some residual risk. Here we describe real-world prevalence and consequences of hypertriglyceridemia. We used large patient databases: NHANES (2007-2014), Optum Research Database, and electronic medical records from two Kaiser Permanente regions. NHANES data revealed that ~26% of US adults, including nearly one-third of statin users, have at least borderline hypertriglyceridemia (triglycerides ≥150 mg/dL), and ~40% of adults with diabetes have levels of ≥150 mg/dL despite statin use. Optum analyses demonstrated that patients with triglycerides ≥150 mg/dL on statins have significantly increased risk of composite initial major cardiovascular events (HR, 1.26; 95% CI, 1.19-1.34; P<0.001 versus patients with triglycerides <150 mg/dL). This was accompanied by increased healthcare utilization and direct healthcare costs (HR, 1.12; 95% CI, 1.08-1.16; P<0.001). In the Kaiser analyses, patients with diabetes and triglycerides 200-499 mg/dL had significantly higher adjusted incidences of non-fatal myocardial infarction (rate ratio 1.30; 95% CI 1.08-1.58; P=0.006), non-fatal stroke (1.23; 1.01-1.49; P=0.037), and coronary revascularization (1.21; 1.02-1.43; P=0.027), but not unstable angina (1.33; 0.87-2.03; P=0.185) compared with patients with triglycerides <150 mg/dL. Real-world analyses suggest that elevated triglycerides are prevalent and commonly associated with increased cardiovascular risk. Cardiovascular outcomes trials in patients with established hypertriglyceridemia will clarify if strategies to reduce triglycerides can ameliorate residual cardiovascular risk in patients taking statins. This article is protected by copyright. All rights reserved.